James Howard Tonsgard to Follow-Up Studies
This is a "connection" page, showing publications James Howard Tonsgard has written about Follow-Up Studies.
Connection Strength
0.044
-
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.
Score: 0.027
-
Cerebral malformations in Carpenter syndrome. Pediatr Neurol. 1993 May-Jun; 9(3):230-4.
Score: 0.017